Stephen C. Rubin, MD

Stephen Rubin, MD

Request an Appointment

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427

Professor, Department of Surgical Oncology

Paul Grotzinger and Wilbur Raab Chair in Surgical Oncology

Specialties

  • Gynecologic Oncology

Areas of Expertise

Ovarian & Primary Peritoneal Cancer, Endometrial (Uterine) Cancer, Vulvar Cancer, Cervical Cancer, Uterine Sarcoma

Treatment Focus

Surgery and chemotherapy for all gynecologic cancers; minimally invasive surgery for gynecologic cancers, precancerous conditions and benign gynecologic conditions

Distinctions

Treatment Philosophy

I joined Fox Chase Cancer Center in 2014 as chief of the Division of Gynecologic Oncology. I spent the early part of my medical career at Memorial Sloan-Kettering Cancer Center in New York and the Hospital of the University of Pennsylvania, where I was chief of gynecologic oncology. As a gynecologic oncologist, I have extensive training and experience in surgery (including minimally invasive) for gynecologic cancers and for complex benign gynecologic conditions. I also provide the full range of chemotherapy options for gynecologic cancers, giving my patients the continuity of care that comes with multimodal cancer care.

I am delighted to be practicing at Fox Chase, where I offer patients state-of-the-art care, including innovative clinical trials, in a caring, compassionate environment, with all the support services that come from an NCI-designated Comprehensive Cancer Center.

Educational Background

  • Fellow, Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1982
  • Resident, Obstetrics & Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1980
  • MD, University of Pennsylvania School of Medicine, Philadelphia, PA, 1976

Certifications

  • American Board of Obstetrics and Gynecology
  • American Board of Obstetrics and Gynecology - Gynecologic Oncology

Memberships

  • American Association of Gynecologic Laparoscopists
  • American College of Obstetricians and Gynecologists
  • American College of Surgeons
  • American Federation for Clinical Research
  • American Gynecological and Obstetrical Society
  • American Radium Society
  • American Society of Clinical Oncology
  • American Society for Colposcopy and Cervical Cytology
  • Association of Professors of Gynecology and Obstetrics
  • Society of Gynecologic Oncologists
  • Society for Gynecologic Investigation
  • Society of Pelvic Surgeons
  • Society of Surgical Oncology
  • International Gynecologic Cancer Society
  • European Society of Gynecological Oncology
  • Felix Rutledge Society
  • New York Academy of Sciences
  • New York Obstetrical Society
  • New York Gynecological Society
  • Obstetrical Society of Philadelphia
  • Philadelphia Colposcopy Society
  • Philadelphia College of Physicians
  • Mid-Atlantic Gynecologic Oncology Society

Honors & Awards

  • Philadelphia Magazine Top Doctors, 1993-2024
  • Best Doctors in America® , 2014, 2019-2020
  • America’s Top Doctors®, 2015-17
  • MA honoris causa, University of Pennsylvania, 1994
  • Presidential Award, Society of Gynecologic Oncologists, 1993
  • Boyer Award for Clinical Investigation, Memorial Sloan-Kettering Cancer Center, 1990
  • Clinical Oncology Career Development Award, American Cancer Society, 1987-90
  • Chief Resident's Teaching Award, Medical College of Pennsylvania, 1983
  • Clinical Fellow, American Cancer Society, 1980-82
Link to /sites/default/files/styles/patient_story/public/images/patient-stories/Miriam%20Headshot.jpg?h=9e084b65&itok=gJ-dlDx-

Miriam Lieberman

  • Breast Cancer
  • Uterine Sarcoma

For decades, my healthcare routine was the same: When I scheduled my annual mammogram to screen for breast cancer, I also booked an appointment for a preventative transvaginal ultrasound. That’s because my sister survived a bout with uterine cancer 40 years ago, and our family history could put me at risk of developing the same cancer.

VIEW PATIENT STORY

Research Interests

  • Clinical trials and innovative therapies for gynecologic cancers

Selected Publications

Resilience, Positive Coping, and Quality of Life Among Women Newly Diagnosed With Gynecological Cancers. Manne SL, Myers-Virtue S, Kashy D, Ozga M, Kissane D, Heckman C, Rubin SC, Rosenblum N. Cancer Nurs. 2015 Sep-Oct;38(5):375-82. doi: 10.1097/NCC.0000000000000215.

Correlation of pelvic magnetic resonance imaging diagnosis with pathology for indeterminate adnexal masses. Haggerty AF, Hagemann AR, Chu C, Siegelman ES, Rubin SC. Int J Gynecol Cancer. 2014 Sep;24(7):1215-21. doi: 10.1097/IGC.0000000000000203. PMID: 25153677

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17. PMID: 24637999

Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease. Clayton EF, Rubin SC, Dumoff KL. Int J Surg Pathol. 2014 Jun;22(4):374-7. doi: 10.1177/1066896913498819. Epub 2013 Aug 5. PMID: 23918905

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Cancer Immunol Immunother. 2012 May;61(5):629-41. doi: 10.1007/s00262-011-1081-8. Epub 2011 Oct 22. PMID: 22021066

A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC. Gynecol Oncol. 2011 Dec;123(3):486-91. doi: 10.1016/j.ygyno.2011.08.032. Epub 2011 Sep 25. PMID: 21945552

Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ Jr, Feldman MD, Coukos G. Cancer Biol Ther. 2011 Aug 15;12(4):367-77. Epub 2011 Aug 15. PMID: 21785280

Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G. Cancer Biol Ther. 2011 Aug 15;12(4):357-66. Epub 2011 Aug  15. PMID: 21785264

Clinical predictors of bevacizumab-associated gastrointestinal perforation. Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, Chu CS. Gynecol Oncol. 2011 Mar;120(3):464-9. doi: 10.1016/j.ygyno.2010.11.009. Epub 2010 Dec 17. PMID: 21168199

Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity. Liao JB, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, Lin LL, McGrath CM, Rubin SC. Gynecol Oncol. 2011 Jan;120(1):108-12. doi: 10.1016/j.ygyno.2010.09.005. PMID: 20937524

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...